Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
AUTOR(ES)
Bitencourt, Roberta, Zalcberg, Ilana, Louro, Iúri Drumond
FONTE
Revista Brasileira de Hematologia e Hemoterapia
DATA DE PUBLICAÇÃO
2011-12
RESUMO
The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing high performance liquid chromatography and allele specific polymerase chain reaction. Mutation analysis has become mandatory during patient workup of chronic myeloid leukemia in order for the physician to choose the most suitable tyrosine kinase inhibitor. This article, a review of possible therapies used to overcome imatinib resistance, investigates the current position by searching the PubMed electronic database using the following keywords: imatinib, dasatinib, nilotinib, aurora kinase, SRC kinase, mutation, treatment, drugs and resistance. New tyrosine kinase inhibitors include BCR-ABL kinase selective inhibitors, dual ABL/SRC kinase inhibitors and aurora kinase inhibitors. Awareness of the spectrum of new drugs against mutations, in particular the T315I mutation, makes it possible to properly select the best therapy for each patient.
Documentos Relacionados
- Monitoring imatinib plasma concentrations in chronic myeloid leukemia
- Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
- Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
- Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
- Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
